CERT

Certara, Inc. NASDAQ

Healthcare ·Medical - Healthcare Information Services ·US · certara.com

$6.19

Mkt Cap $949.1M

52w Low $5.19 11.5% of range 52w High $13.88

50d MA $6.28 200d MA $9.16

P/E (TTM) -618.0x

EV/EBITDA 14.7x

P/B 0.9x

Debt/Equity 0.0x

ROE -0.1%

P/FCF 14.9x

RSI (14) —

ATR (14) —

Beta 1.62

50d MA $6.28

200d MA $9.16

Avg Volume 3.8M

About

Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to gu…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 26, 2026	AMC	0.11	0.09	-18.2%	6.80	-1.5%	+4.1%	+3.7%	+6.5%	+8.1%	+5.1%	—
Nov 6, 2025	AMC	0.11	0.14	+27.3%	11.27	-1.9%	-23.1%	-23.5%	-23.9%	-26.5%	-25.4%	—
Aug 6, 2025	AMC	0.10	0.07	-30.0%	9.53	+7.0%	+18.2%	+14.8%	+9.9%	+12.8%	+17.2%	—
May 5, 2025	AMC	0.13	0.14	+7.7%	12.78	+2.6%	-11.0%	-10.3%	-7.1%	-6.3%	-5.1%	—
Feb 26, 2025	AMC	0.13	0.15	+15.4%	12.33	+6.1%	+0.6%	-2.8%	-3.2%	-3.9%	-3.4%	—
Nov 6, 2024	AMC	0.11	0.13	+18.2%	10.91	-1.2%	+0.7%	+1.1%	-0.2%	-2.8%	-1.8%	—
Aug 6, 2024	AMC	0.11	0.07	-36.4%	15.08	-10.5%	-13.6%	-13.3%	-17.0%	-20.4%	-17.4%	—
May 7, 2024	AMC	0.10	0.10	+0.0%	17.66	-4.6%	-7.4%	-3.4%	-3.7%	-5.7%	-7.0%	—
Feb 29, 2024	AMC	0.11	0.09	-18.2%	16.88	+5.2%	+8.4%	+11.8%	+10.2%	+12.9%	+15.2%	—
Nov 8, 2023	AMC	0.11	0.11	+0.0%	12.48	+5.6%	+1.4%	+8.2%	+4.3%	+16.1%	+18.0%	—
Aug 9, 2023	AMC	0.13	0.12	-7.7%	17.92	-13.5%	-7.6%	-7.0%	-4.1%	-5.7%	-7.4%	—
May 8, 2023	AMC	0.12	0.12	+0.0%	23.42	-8.9%	-10.7%	-10.5%	-10.4%	-13.2%	-13.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 13	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$5.55	$5.53	-0.4%	+4.3%	+4.9%	+10.8%	+11.0%	+12.1%
Mar 6	Barclays	Downgrade	Overweight → Equal Weight	—	$7.15	$6.92	-3.2%	-1.3%	-1.5%	-3.1%	-6.9%	-8.3%
Feb 27	Barclays	Maintains	Overweight → Overweight	—	$6.80	$6.70	-1.5%	+4.1%	+3.7%	+6.5%	+8.1%	+5.1%
Jan 8	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$9.49	$9.50	+0.1%	+1.9%	-1.7%	-1.1%	-3.6%	-1.8%
Jan 6	Leerink Partners	Upgrade	Market Perform → Outperform	—	$9.04	$9.43	+4.3%	+5.9%	+5.0%	+7.0%	+3.2%	+3.9%
Dec 18	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$8.86	$8.87	+0.1%	+0.2%	+2.4%	+2.8%	+1.2%	+0.6%
Dec 15	Barclays	Maintains	Overweight → Overweight	—	$8.58	$8.66	+0.9%	+1.9%	+0.9%	+3.3%	+3.5%	+5.7%
Dec 12	Stephens & Co.	Maintains	Overweight → Overweight	—	$8.81	$8.79	-0.2%	-2.6%	-0.8%	-1.7%	+0.6%	+0.8%
Nov 7	Barclays	Maintains	Overweight → Overweight	—	$11.27	$11.06	-1.9%	-23.1%	-23.5%	-23.9%	-26.5%	-25.4%
Oct 8	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$12.93	$13.23	+2.3%	+0.5%	+0.1%	-8.3%	-5.3%	-8.0%
Oct 2	Barclays	Maintains	Overweight → Overweight	—	$13.37	$13.48	+0.8%	+1.7%	-2.2%	+0.6%	-3.3%	-2.8%
Aug 7	UBS	Maintains	Buy → Buy	—	$9.53	$10.20	+7.0%	+18.2%	+14.8%	+9.9%	+12.8%	+17.2%
Jul 14	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$11.09	$11.03	-0.5%	+0.5%	-6.1%	-6.1%	-5.0%	-8.9%
May 8	Barclays	Upgrade	Equal Weight → Overweight	—	$11.46	$12.17	+6.2%	+3.6%	+4.5%	+5.8%	+5.9%	+2.3%
May 6	JMP Securities	Maintains	Market Perform → Market Perform	—	$12.78	$13.11	+2.6%	-11.0%	-10.3%	-7.1%	-6.3%	-5.1%
Apr 16	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$13.88	$14.01	+0.9%	-2.5%	+1.9%	+4.3%	+4.1%	+2.7%
Apr 11	Baird	Maintains	Neutral → Neutral	—	$10.51	$11.84	+12.7%	+22.8%	+37.0%	+32.1%	+28.7%	+34.6%
Apr 10	Barclays	Maintains	Equal Weight → Equal Weight	—	$9.73	$9.49	-2.5%	+8.0%	+32.7%	+48.0%	+42.7%	+39.1%
Feb 28	Barclays	Maintains	Equal Weight → Equal Weight	—	$12.40	$12.21	-1.5%	-3.4%	-3.7%	-4.4%	-4.0%	-6.3%
Feb 27	Stephens & Co.	Maintains	Overweight → Overweight	—	$12.33	$13.08	+6.1%	+0.6%	-2.8%	-3.2%	-3.9%	-3.4%
Nov 7	Barclays	Maintains	Equal Weight → Equal Weight	—	$10.91	$10.78	-1.2%	+0.7%	+1.1%	-0.2%	-2.8%	-1.8%
Nov 5	Baird	Maintains	Neutral → Neutral	—	$10.25	$10.12	-1.3%	+0.6%	+6.4%	+7.2%	+7.6%	+6.2%
Oct 15	Barclays	Maintains	Equal Weight → Equal Weight	—	$11.24	$11.19	-0.4%	-0.3%	-0.2%	+2.9%	+1.5%	-0.4%
Sep 27	UBS	Upgrade	Neutral → Buy	—	$10.70	$11.59	+8.3%	+9.8%	+9.4%	+6.1%	+6.3%	+2.7%
Aug 7	Baird	Maintains	Neutral → Neutral	—	$15.08	$13.49	-10.5%	-13.6%	-13.3%	-17.0%	-20.4%	-17.4%
Aug 7	UBS	Maintains	Neutral → Neutral	—	$15.08	$13.49	-10.5%	-13.6%	-13.3%	-17.0%	-20.4%	-17.4%
Jul 11	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$13.88	$14.01	+0.9%	+8.9%	+9.4%	+12.8%	+18.9%	+19.2%
Jun 28	Barclays	Maintains	Equal Weight → Equal Weight	—	$13.65	$13.74	+0.7%	+1.5%	-0.1%	+0.1%	+1.4%	+4.2%
Apr 10	KeyBanc Capital Markets	Upgrade	Sector Weight → Overweight	—	$18.51	$18.20	-1.7%	-0.3%	-0.3%	-4.5%	-5.8%	-7.8%
Mar 1	UBS	Maintains	Neutral → Neutral	—	$16.88	$17.75	+5.2%	+8.4%	+11.8%	+10.2%	+12.9%	+15.2%
Mar 1	Jefferies	Maintains	Hold → Hold	—	$16.88	$17.75	+5.2%	+8.4%	+11.8%	+10.2%	+12.9%	+15.2%
Jan 25	Barclays	Maintains	Equal Weight → Equal Weight	—	$16.10	$16.35	+1.6%	+0.2%	+3.2%	+2.5%	+1.9%	+0.4%
Oct 11	Stephens & Co.	Maintains	Overweight → Overweight	—	$14.36	$14.38	+0.1%	-0.6%	-3.4%	-4.3%	-2.8%	-1.9%
Aug 22	Jefferies	Downgrade	Buy → Hold	—	$16.11	$15.45	-4.1%	-2.7%	-0.7%	-1.4%	+0.1%	-1.2%
Aug 15	BofA Securities	Maintains	Buy → Buy	—	$17.19	$17.09	-0.6%	-1.7%	-3.4%	-5.6%	-6.7%	-6.3%
Aug 11	Barclays	Maintains	Equal Weight → Equal Weight	—	$16.55	$16.47	-0.5%	+0.7%	+3.9%	+2.1%	+0.3%	-1.9%
Aug 10	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$17.92	$15.50	-13.5%	-7.6%	-7.0%	-4.1%	-5.7%	-7.4%
Aug 10	William Blair	Downgrade	Outperform → Market Perform	—	$17.92	$15.50	-13.5%	-7.6%	-7.0%	-4.1%	-5.7%	-7.4%
Aug 10	Credit Suisse	Maintains	Outperform → Outperform	—	$17.92	$15.50	-13.5%	-7.6%	-7.0%	-4.1%	-5.7%	-7.4%
Jul 27	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$19.26	$19.36	+0.5%	-3.2%	-0.5%	+1.1%	-0.8%	-3.4%
Apr 4	Barclays	Downgrade	Overweight → Equal Weight	—	$23.57	$23.74	+0.7%	-2.0%	-2.9%	-2.4%	-2.1%	-1.9%
Apr 3	Barclays	Downgrade	Overweight → Equal Weight	—	$24.11	$23.12	-4.1%	-2.2%	-4.2%	-5.1%	-4.6%	-4.3%
Mar 27	Credit Suisse	Maintains	Outperform → Outperform	—	$23.65	$24.02	+1.6%	+0.8%	+0.6%	+0.9%	+0.6%	+1.9%
Mar 10	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$21.06	$21.06	+0.0%	-7.3%	-3.5%	-1.7%	-2.4%	+8.2%
Mar 2	Credit Suisse	Maintains	Outperform → Outperform	—	$18.44	$20.20	+9.5%	+17.3%	+17.8%	+16.4%	+14.9%	+15.3%
Mar 2	Barclays	Maintains	Overweight → Overweight	—	$18.44	$20.20	+9.5%	+17.3%	+17.8%	+16.4%	+14.9%	+15.3%
Jan 24	Barclays	Maintains	Overweight → Overweight	—	$18.73	$18.83	+0.5%	-1.4%	-0.3%	+1.9%	+2.1%	+0.5%
Dec 14	Baird	Downgrade	Outperform → Neutral	—	$17.40	$17.05	-2.0%	-6.4%	-5.7%	-7.1%	-7.1%	-6.3%
Nov 14	Credit Suisse	Maintains	Outperform → Outperform	—	$14.65	$14.54	-0.8%	-0.1%	+6.3%	+2.5%	-3.3%	+2.9%
Oct 6	Barclays	Maintains	Overweight → Overweight	—	$13.95	$13.91	-0.3%	-2.3%	-6.0%	-10.0%	-10.8%	-14.1%

Recent Filings

8-K · 1.01 !! High

Certara, Inc. -- 8-K 1.01: Material Agreement

Certara acquired Veristat, LLC for $100 million, expanding its regulatory and clinical trial solutions capabilities through this strategic acquisition.

Apr 22

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

CERT's departure of a key executive signals potential leadership instability and strategy uncertainty, likely pressuring the stock until succession clarity emerges and investor confidence in continuity strengthens.

Mar 31

8-K

Certara, Inc. -- 8-K Filing

Certara reported modest 3% Q4 revenue growth to $103.6M with declining adjusted EBITDA, guiding 2026 revenue growth of 0-4% and adjusted EPS of $0.44-$0.48, signaling slowing momentum.

Feb 26

Data updated apr 25, 2026 12:48am · Source: massive.com